Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
马萨诸塞州弗雷明翰/ACCESSWIRE/2022年9月7日亚洲网加利福尼亚州圣克拉拉9月23日电致力于推进用于治疗难治性癌症的创新免疫肿瘤学技术的生物制药公司Xenetic Biosciences，Inc.(纳斯达克代码：XBIO)(以下简称“Xenetic”或“公司”)今天宣布，Xenetic首席执行官杰弗里·F·艾森伯格将出席2022年9月12-14日在纽约举行的H.C.Wainwright第24届全球投资年会。
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
除了介绍外，管理层还可以参加虚拟的一对一会议，与注册参加会议的投资者群体中合格的成员举行会议。欲了解更多信息，请访问大会网站。
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 12 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company's website (). The webcast replay will be archived for 90 days following the event.
9月12日(星期一)美国东部时间上午7：00起，已注册参加活动的人员可通过视频网络直播观看演示文稿，并可在公司网站投资者部分的活动页面上观看()。网络直播重播将在活动结束后90天内存档。
About Xenetic Biosciences
关于遗传生物科学
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Xenetic Biosciences，Inc.是一家生物制药公司，专注于推进创新的免疫肿瘤学技术，以解决难以治疗的癌症。该公司的DNase平台旨在通过瞄准与癌症进展有关的中性粒细胞外陷阱(Net)来改善包括免疫疗法在内的现有治疗的结果。Xenetic目前专注于将其全身性DNA ase计划推向临床，作为胰腺癌和局部晚期或转移性实体肿瘤的辅助治疗。
The Company is also developing its personalized CAR T platform technology, XCARTT, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
该公司还在开发其个性化CAR T平台技术XCARTT，以开发针对单个患者恶性肿瘤细胞表面独特的B细胞受体的基于细胞的疗法，用于治疗B细胞淋巴瘤。
For more information, please visit the Company's website at and connect on Twitter, LinkedIn, and Facebook.
欲了解更多信息，请访问公司网站，并连接Twitter、LinkedIn和Facebook。
CONTACT:
联系方式：
JTC Team, LLC
JTC团队，有限责任公司
Jenene Thomas
珍妮·托马斯
(833) 475-8247
(833) 475-8247
xbio@jtcir.com
邮箱：xbio@jtCir.com
SOURCE: Xenetic Biosciences, Inc.
资料来源：Xenetic生物科学公司。
View source version on accesswire.com:
在accesswire.com上查看源代码版本：
COMTEX_413919573/2457/2022-09-07T08:05:37
COMETX_413919573/2457/2022-09-07T08：05：37